申国璋,沈向前,胡信群,方臻飞,唐建军,周滔,吕晓玲

• 1: 中南大学湘雅二医院心导管室
• 2:中南大学湘雅二医院心导管室
• 3:中南大学湘雅二医院心导管室
• 4:中南大学湘雅二医院心导管室

摘要(Abstract)：

目的观察国产替罗非班对急诊经皮冠状动脉介入治疗(PCI)患者血小板聚集率和临床结果的影响,进而评价其在急诊PCI中的疗效和安全性。方法2005年9月至2006年3月30例在中南大学湘雅二医院行急诊PCI的患者(均为ST段抬高心肌梗死患者)入选替罗非班组,同期相匹配的30例行择期PCI的患者入选对照组。替罗非班组在PCI术前第10~30分静脉注射替罗非班10μg/kg(3min注完),然后以0.15μg/(kg.min)静脉滴注维持36h,对照组以相同的方法输注安慰剂。所有患者均接受静脉注射普通肝素及口服二磷酸腺酐(ADP)受体拮抗剂和阿司匹林。观察两组血小板聚集率、7d和30d复合终点事件发生率(死亡、顽固性心肌缺血、再发心肌梗死和靶血管重建术)和出血事件。结果与对照组相比,替罗非班组血小板聚集率明显下降[(19±8)%比(54±7)%,P<0.001];7d和30d复合终点事件发生率未见差别(16.7%比6.7%,P=0.42;30.0%比13.3%,P=0.21);替罗非班组出血事件有增多趋势(26.7%比3.3%,P=0.026),主要是穿刺点出血,二组均无颅内出血等严重出血事件发生。结论替罗非班对急诊PCI患者是安全有效的。

关键词(KeyWords)： 心肌梗死;血管成形术,经腔,经皮冠状动脉;血小板聚集

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 申国璋,沈向前,胡信群,方臻飞,唐建军,周滔,吕晓玲

参考文献(References)：

• [1]The RESTOREInvestigators.Effect of platelet glycoproteinⅡb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction.Circulation,1997,96:1445-1453.
• [2]The TACTICS-TIMI18Investigators.Comparison of early invasive and conservative strgegies in patients with unstable coronary syndromes treated with platelet glycoproteinⅡb/Ⅲa inhibitor tirofiban.NEngl J Med,2001,344:1879-1887.
• [3]The TIGER-PAInvestigators.Adjunctive platelet glycoproteinⅡb/Ⅲa receptor inhibition with tirofiban before primary angioplasty improves angiopraphic outcomes.Circulation,2003,107:1497-1501.
• [4]Alpert JS,Thygesen K,Antman E,et al.Myocardial infarctionredefined——a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.J Am Coll Cardiol,2000,36:959-969.
• [5]Rao AK,Pratt C,Berke A,et al.Thrombolysis in Myocardial Infarction(TIMI)Trial-phase I:hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic systemin patients with recombinant tissue plasminogen activator and streptokinase.J Am Coll Cardiol,1988,11:1-11.
• [6]Metha SR,Yusuf S,Peters RJ,et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoning percutaneous coronary interventions:PCI-CURE study.Lancet,2001,358:527-533.
• [7]霍勇.冠心病介入治疗围手术期的抗血小板治疗.中国实用内科杂志,2005,25:593-594.
• [8]Steinhubl SR,Berger PB,Mann JT3rd,et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trail.JAMA,2002,288:2411-2420.
• [9]Patrono C,Oller B,FitzGerald GA,et al.Platelet-active drugs:the relationships among dose,effectiveness,andside effects:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest,2004,126:234s-264.